2024
Efficacy of long‐term risankizumab treatment for moderate‐to‐severe plaque psoriasis: Subgroup analyses by baseline characteristics and psoriatic disease manifestations through 256 weeks (LIMMitless trial)
Strober B, Bachelez H, Crowley J, Elewski B, Gooderham M, Menter A, Strohal R, Chen M, Wu T, Zhan T, Photowala H, Armstrong A. Efficacy of long‐term risankizumab treatment for moderate‐to‐severe plaque psoriasis: Subgroup analyses by baseline characteristics and psoriatic disease manifestations through 256 weeks (LIMMitless trial). Journal Of The European Academy Of Dermatology And Venereology 2024, 38: 864-872. PMID: 38179809, DOI: 10.1111/jdv.19748.Peer-Reviewed Original ResearchSevere plaque psoriasisLong-term efficacyPlaque psoriasisDisease manifestationsWeek 256Palmoplantar psoriasisSubgroup analysisDurable long-term efficacyOpen-label extension studyBaseline patient characteristicsProportion of patientsBody mass indexInflammatory skin diseaseMultiple clinical manifestationsPASI 90/100Psoriatic manifestationsRisankizumab treatmentBaseline characteristicsPatient characteristicsPsoriasis AreaSkin psoriasisMass indexClinical manifestationsArthritis statusPatient subgroups
2023
43944 Improvements in Manifestations of Active Psoriatic Arthritis With Risankizumab Treatment After Intolerance or Inadequate Response to Prior Biologic Therapy: Subgroup Analyses From the KEEPsAKE 2 Trial
Strober B, Kivitz A, Östör A, Padilla B, Yue C, Photowala H, Merola J. 43944 Improvements in Manifestations of Active Psoriatic Arthritis With Risankizumab Treatment After Intolerance or Inadequate Response to Prior Biologic Therapy: Subgroup Analyses From the KEEPsAKE 2 Trial. Journal Of The American Academy Of Dermatology 2023, 89: ab179. DOI: 10.1016/j.jaad.2023.07.717.Peer-Reviewed Original Research
2021
Effect of baseline disease severity on achievement of treatment target with apremilast: results from a pooled analysis
Reich K, Mrowietz U, Menter A, Griffiths C, Bagel J, Strober B, Gomez N, Shi R, Guerette B, Lebwohl M. Effect of baseline disease severity on achievement of treatment target with apremilast: results from a pooled analysis. Journal Of The European Academy Of Dermatology And Venereology 2021, 35: 2409-2414. PMID: 34255891, DOI: 10.1111/jdv.17520.Peer-Reviewed Original ResearchConceptsDermatology Life Quality IndexWeek 32Treatment targetsPooled analysisNail Psoriasis Severity IndexGlobal assessmentPhysician global assessmentSevere plaque psoriasisBaseline disease severitySeverity IndexPsoriasis Severity IndexLong-term outcomesLife Quality IndexSevere skin diseaseImportant clinical conceptsESTEEM 1Plaque psoriasisDisease durationMost patientsPsoriasis AreaModerate diseasePsoriasis severityDisease characteristicsPsoriasis guidelinesSubgroup analysis
2013
Dose Response and Pharmacokinetics of Tofacitinib (CP‐690,550), an Oral Janus Kinase Inhibitor, in the Treatment of Chronic Plaque Psoriasis
Tan H, Gupta P, Harness J, Wolk R, Chapel S, Menter A, Strober B, Langley R, Krishnaswami S, Papp K. Dose Response and Pharmacokinetics of Tofacitinib (CP‐690,550), an Oral Janus Kinase Inhibitor, in the Treatment of Chronic Plaque Psoriasis. CPT Pharmacometrics & Systems Pharmacology 2013, 2: 1-8. PMCID: PMC3674331, DOI: 10.1038/psp.2013.22.Peer-Reviewed Original ResearchBody weightPlacebo-controlled dose-ranging studyOral Janus kinase inhibitorPhase III clinical trialsPharmacokinetics of tofacitinibChronic plaque psoriasisDose-ranging studyPlaque psoriasis treatmentJanus kinase inhibitorNonlinear mixed-effects modelingTofacitinib 2Tofacitinib 5Confirmatory phase III clinical trialDose-response profilesPlaque psoriasisSystemic exposurePsoriasis treatmentSubgroup analysisMixed-effects modelingClinical trialsClinical dataTofacitinibPsoriasisKinase inhibitorsReduced efficacy